El consumo de dos kiwis diarios podría mejorar el hábito intestinal en personas con estreñimiento crónico / Daily consumption of two kiwifruits could improve bowel habits in people with chronic constipation

A partir del caso de una paciente con síndrome de intestino irritable a predominio de estreñimiento cuyos síntomas mejoraron con el consumo regular de kiwi, el médico de familia se planteó la pregunta de si el kiwi podría mejorar los síntomas asociados a constipación crónica en comparación con el tratamiento habitual. Tras realizar una búsqueda de estudios que analizaran los efectos del consumo de kiwi sobre el hábito intestinal, fueron seleccionados tres artículos que permiten concluir que el consumo de esta fruta tiene una eficacia superior al placebo y comparable al psyllium y las pasas de ciruela para mejorar los síntomas de personas con estreñimiento crónico. (AU)

Based on the case of a patient with constipation-predominant irritable bowel syndrome whose symptoms improved with regular consumption of kiwi, the family doctor wondered if kiwi could improve symptoms associated with chronic constipation compared to usual treatment. After conducting a search for studies that analyzed the effects of kiwi consumption on intestinal habit, three articles were selected that allow us to conclude that the consumption of this fruit has an efficacy superior to placebo and comparable to psyllium and plum raisins to improve the symptoms of people with chronic constipation. (AU)

Estimulação elétrica nervosa transcutânea (tens) e ultrassom para os sintomas da síndrome do intestino irritável: um estudo de caso / Transcutaneous nervous electrical stimulation (tens) and ultrasound for irritable bowel syndrome symptoms: a case study / Estimulación nerviosa eléctrica transcutánea (tens) y ultrasonido para los síntomas del síndrome del intestino irritable: un estudio de casos

Introdução: O intestino é um órgão vital, entretanto, seu mau funcionamento pode gerar alguns distúrbios como por exemplo, "A síndrome do intestino irritável". O quadro desses pacientes são dores na barriga, inchaço abdominal e alteração na frequência das evacuações e na consistência das fezes. A fisioterapia tem apresentado meios que favorecem analgesia. Objetivo: Verificar os efeitos da Estimulação Elétrica Nervosa Transcutânea (TENS) e do Ultrassom (US) nos sintomas da síndrome do intestino irritável. Método: Foi utilizado o TENS na região abdominal, durante 15 minutos. O Ultrassom foi usado durante 3 minutos em cada região abdominal, somando 12 minutos ao total. O tratamento foi realizado durante um mês, com 9 sessões. Utilizou-se a Escala Visual Analógica (EVA) e o questionário Inflammatory Bowel Disease Questionnaire (IBDQ). Resultados: Nos sintomas intestinais obteve-se progresso de 5 pontos no questionário IBDQ e nos sintomas emocionais houve uma evolução de 9 pontos, sendo este, estatisticamente significante. Na escala EVA a média de escore diminui de 5,6 para 3,6 ao final da intervenção. Conclusão: A intervenção fisioterapêutica surtiu efeitos positivos e contribuiu para a diminuição da dor e os outros sintomas como: inchaço abdominal e diminuição na quantidade de evacuações e essa evolução auxiliou na qualidade de vida do voluntário.

Introduction: The intestine is a vital organ, however, due to its malfunction, some disorders appear, for example, "The irritable bowel syndrome", patients with this syndrome experience pain in the belly, abdominal swelling, changes in the frequency of bowel movements and stool consistency. Physiotherapy uses means that help to cause analgesia. Objective: To verify the effects of TENS and Ultrasound on the symptoms of the individual with irritable bowel syndrome, contributing to the quality of life. Method: TENS was used in the abdominal region in Burst mode with a frequency of 150Hz with amplitude until it caused a slight contraction, for 15 minutes. Ultrasound was used in continuous mode with a frequency of 1MHZ, with a dose of 0.5w / cm2, for 3 minutes in each abdominal region, adding 12 minutes to the total. The treatment was carried out for one month, with 9 sessions. The EVA scale and the IBDQ questionnaire were used. Results: In the intestinal symptoms there was an improvement of 5 points in the IBDQ questionnaire and in the emotional aspect there was an improvement of 9 points and in the emotional aspect it was statistically significant, passing through the Wilcoxon test, P (est.) = 0.031 P (exact) ) = 0.031. On the EVA scale, the mean score before the intervention was 5.6 and at the end 3.6. Conclusion: The physical therapy intervention had positive effects, helping to reduce pain and other symptoms such as:abdominal swelling, decrease in the amount of bowel movements and this improvement helped the individual's emotional state, however a study on the subject is still necessary.

Introducción: El intestino es un órgano vital, sin embargo, su mal funcionamiento puede generar algunos trastornos como el "síndrome del intestino irritable". Los síntomas de estos pacientes son dolor de estómago, hinchazón abdominal y alteración de la frecuencia de las deposiciones y de la consistencia de las heces. La fisioterapia ha presentado medios que favorecen la analgesia. Objetivo: Verificar los efectos de la Estimulación Nerviosa Eléctrica Transcutánea (TENS) y el Ultrasonido (US) en los síntomas del síndrome del intestino irritable. Método: Se utilizó TENS en la región abdominal durante 15 minutos. Los ultrasonidos se utilizaron durante 3 minutos en cada región abdominal, sumando 12 minutos en total. El tratamiento se llevó a cabo durante un mes, con 9 sesiones. Se utilizaron la Escala Visual Analógica (EVA) y el Cuestionario de Enfermedad Inflamatoria Intestinal (IBDQ). Resultados: En los síntomas intestinales hubo una progresión de 5 puntos en el cuestionario IBDQ y en los síntomas emocionales hubo una evolución de 9 puntos, siendo esto, estadísticamente significativo. En la escala VAS, la puntuación media disminuyó de 5,6 a 3,6 al final de la intervención. Conclusión: La intervención fisioterapéutica tuvo efectos positivos y contribuyó a la reducción del dolor y de otros síntomas como: hinchazón abdominal y disminución de la cantidad de deposiciones y esta evolución ayudó a la calidad de vida del voluntario.

Artículo de revisión: abordaje del síndrome de intestino irritable en APS / Review article: Irritable bowel syndrome approach in PHC

El síndrome de intestino irritable es un trastorno digestivo funcional recientemente reconocido como una alteración en el nivel intestino-cerebral que no se explica por alteraciones morfológicas, metabólicas o neurológicas demostrables por las técnicas diagnósticas habituales, caracterizándose por la presencia de dolor y distensión abdominal recurrente asociado a alteraciones del ritmo deposicional, ya sea en forma de constipación, diarrea o ambas. La prevalencia oscila entre los 6-11% dependiendo de los criterios diagnósticos utilizados y la zona geográfica, en Chile no hay datos actuales. Su fisiopatología es multifactorial, donde ninguno explica por si solo el síndrome. El diagnóstico es positivo basado en los criterios de Roma IV establecidos en el año 2016, a su vez es imperante establecer un subtipo de SII para realizar el manejo adecuado, es así como podemos tener un SII con predominio de constipación, diarrea, mixto o indeterminado. El manejo consta de la educación al paciente, una buena relación médico-paciente, dieta adecuada, actividad física aeróbica y otros tratamientos no farmacológicos, sumado a antiespasmódicos, antidiarreicos y fibra soluble, dependiendo del síntoma predominante.

Irritable bowel syndrome (IBS) is a functional digestive disorder recently recognized as an alteration in the gut-brain axis which can´t be explained by morphological, metabolic or neurological alterations demonstrable by the usual diagnostic techniques, characterized by the presence of recurrent abdominal pain and distention associated with alterations in the stool rhythm, either in the form of constipation, diarrhea or both. The prevalence ranges between 6-11% according to the diagnostic criteria used and the geographical area, in Chile there's no current data. Its pathophysiology is multifactorial, where any of them explains the syndrome itself. The diagnosis is positive based on the Rome IV criteria established in 2016, it is imperative to establish a subtype of IBS to carry out the appropriate management, This is how we can have IBS with a predominance of constipation, diarrhea, mixed or indeterminate Management consists of patient education, a good doctor-patient relationship, adequate diet, aerobic physical activity and other non-pharmacological treatments, added to antispasmodics, antidiarrheals and soluble fiber, depending on the predominant symptom.

Prevalencia de síndrome de intestino irritable en América Latina / Irritable bowel syndrome prevalence in Latin America

El síndrome de intestino irritable es una enfermedad funcional intestinal frecuente a nivel mundial, pero con pocos estudios de prevalencia. Su diagnóstico es clínico y se basa en criterios acordados internacionalmente que han cambiado con el tiempo, actualmente regidos por el Consenso de Roma IV. Objetivo: Recabar y actualizar datos disponibles de prevalencia de América Latina para entender mejor el comportamiento regional de SII. Materiales y métodos: Se realizó una búsqueda de trabajos originales, autodefinidos de prevalencia, en las bases de datos Pubmed y Lilacs así como presentaciones en congresos de trabajos originales. Resultados: Se encontraron 27 estudios según los criterios de búsqueda establecidos. De ellos, 16 eran en población general. Dos trabajos incluyeron el estudio de prevalencia de más de una población constituyendo finalmente 22 referencias desarrolladas en 9 países. La prevalencia promedio total para América Latina fue 15,4%. La prevalencia promedio encontrada por criterios de Roma II fue 23,5%; por Roma III 11,8% y por Roma IV 6,98%. Conclusión: Esta es la primera revisión en reunir datos de prevalencia de síndrome de intestino irritable en población general de nueve países de América Latina. La prevalenci d fue amplia y los criterios diagnósticos utilizados hicieron la mayor diferencia.

Although irritable bowel syndrome is a common functional bowel disease worldwide, few prevalence studies have been published. Diagnosis is clinical and based on internationally agreed criteria that have changed over time. Currently the Rome IV Consensus is used as the international reference. Objective: collect and update available prevalence data from Latin America to better understand the regional behavior of irritable bowel syndrome. Materials and methods: a search was carried out for original works, self-defined on prevalence, in the Pubmed and Lilacs databases. Presentations or posters at congresses of original works were also considered. Results: according to the established search criteria, 27 studies were found. Of these, 16 were in the general population. Two studies included the study of the prevalence of more than one population, for which reason 22 prevalence data were obtained from 9 countries. The total average prevalence for Latin America was 15.4%. The average prevalence found by the Rome II criteria was 23.5%; by Rome III 11.8% and by Rome IV 6.98%. Conclusion: this is the first review to collect data on the prevalence of irritable bowel syndrome in the general population from nine Latin American countries. The average prevalence found was 15%. The variability was wide and the diagnostic criteria used made the biggest difference.

Quality of life and psychometric evaluation of patients diagnosed with irritable bowel syndrome: an observational cohort study

ABSTRACT BACKGROUND: Very few data are available for evaluating health-related quality of life among people with irritable bowel syndrome (IBS) and even fewer data are available in relation to anxiety and depression status among these patients. OBJECTIVES: To evaluate the quality of life, anxiety and depression status of patients with IBS. DESIGN AND SETTING: Observational cohort study conducted in a tertiary-care university hospital. METHODS: Patients who had recently been diagnosed with IBS and who had been followed up for IBS-specific treatment for at least three months were included. A quality of life (QoL) survey, the Beck Anxiety Index (BAI) and the Hamilton Depression Index (HAM-D) were applied to the patients. RESULTS: In total, 274 patients with IBS were included in the study cohort. These patients presented very high baseline scores for anxiety and depression, and very poor QoL results. CONCLUSION: Our study showed that IBS had a very high impact on these patients, regarding their anxiety and depression levels, alongside very poor results relating to quality of life.

Probióticos en el síndrome de intestino irritable con predominio de diarrea / Probiotics for the treatment of diarrhea predominant irritable bowel syndrome

Una mujer de 36 años, diagnosticada con síndrome de intestino irritable a predominio de diarrea (SII-D) acude a la consulta médica. Ella pregunta si el uso de probióticos sería útil para controlar los episodios de diarrea, ya que los fármacos con los que está siendo tratada no le resultan eficaces. Se realizó una búsqueda bibliográfica con el objetivo de en contrar evidencia en respuesta a su consulta, tras la cual se seleccionaron dos ensayos clínicos y una revisión sistemática. Se evidenciaron diversos resultados en cuanto al uso de probióticos en el SII-D y se discutieron los riesgos y beneficios del tratamiento, así como las implicancias en la vida de la paciente. (AU)

A 36-year-old woman diagnosed with diarrhea predominant irritable bowel syndrome (D-IBS) goes to meet the doctor. She raises whether the use of probiotics would be useful for controlling diarrhea episodes, since the drugs which she is being treated with, are not effective. A bibliographic search was conducted with the objective of finding evidence in response toher query. Two clinical trials and a systematic review were found. Variable results were found regarding the use of probioticsin D-IBS. The risks and benefits of the treatment were discussed, as well as the implications in the patient's lifestyle. (AU)

Updated analysis of irritable bowel syndrome: a review of the literature / Análisis actualizado del síndrome de intestino irritable: una revisión de la literatura

Irritable bowel syndrome (IBS) is a chronic pathology with disorders of the bowel-brain interaction, characterized by abdominal pain localized anywhere in the abdomen as well as bowel habit alteration (constipation, diarrhea or mixed), in the absence of any disease that can cause these symptoms. With the updated concepts according to the latest meeting of experts in Rome 2016, our goal is to raise awareness about irritable bowel syndrome, by reviewing the literature regarding definition, classification, pathophysiology, clinical aspects, treatment, prognosis and the future. IBS is a chronic pathology, characterized by abdominal pain, at least 1 day per week in the last 3 months, associated with the alteration of the intestinal bowel habits. With a classification based on the alteration of intestinal bowel movements and in addition to constipation induced by opioids or narcotics, the etiology and pathophysiology are not well explained or well-known so far. The clinical aspects are based on the Rome IV criteria. A good doctor-patient relationship is key to reassuring the patient's doubts about his illness, which increases the chances of adherence to individualized treatment from patient to patient depending on the sing and symptoms that may manifest in those that include: dietary advice, psychological support, in some cases pharmacological prescription, suspension of medications or change medications, minimize the dose of drugs or suspend, according to the needs of the patient as is the case of opioids. The prognosis is still uncertain, and a promising future to illustrate new definitions, classifications, pathophysiologies, clinical aspects and treatments according to the type of clinical manifestation of each patient.

El síndrome del intestino irritable (SII) es una patología crónica con desordenes de la interacción cerebro intestino, caracterizado por dolor abdominal localizado en cualquier parte del abdomen además de alteración del hábito intestinal como (constipación, diarrea o mixto), en ausencia de alguna enfermedad que pueda causar estos síntomas. Con los conceptos actualizados conforme en la última reunión de expertos en Roma 2016, nuestra meta es dar a conocer más sobre el síndrome del intestino irritable, mediante revisión de la literatura en cuanto a definición, clasificación, fisiopatología, aspectos clínicos, tratamiento, pronóstico y el futuro. El SII es una patología crónica, caracterizado por dolor abdominal, por lo menos 1 día por semana en los últimos 3 meses, asociado a la alteración del hábito intestinal. Con una clasificación basada en la alteración de los hábitos intestinales y además de constipación inducida por opioides o narcóticos, la etiología y fisiopatología no están bien explicadas ni se conocen bien hasta el momento. Los aspectos clínicos son basados en los criterios de Roma IV. Una buena relación médico-paciente es clave para tranquilizar las dudas del paciente sobre su enfermedad, lo que aumenta las posibilidades de adherencia al tratamiento individualizado de paciente a paciente dependiendo de las sintomatologías y signos que puedan manifestar en los que incluyen: asesoramiento dietético, apoyo psicológico, en algunos casos cambiar medicación, disminuir al mínimo la dosis del medicamento o suspender, según las necesidades del paciente como son los casos de los opiodes. El pronóstico todavía incierto, y un futuro prometedor para ilustrar nuevas definiciones, clasificaciones, fisiopatologías, aspectos clínicos, tratamientos posiblemente de acuerdo con el tipo de manifestación clínica de cada paciente.

Caracterización y subtipos del síndrome de intestino irritable en niños de Panamá, Ecuador, El Salvador, Nicaragua y México / Irritable bowel syndrome subtypes and characteristics in children from Panama, Ecuador, El Salvador, Nicaragua and Mexico

Introducción: Pocos estudios pediátricos clasifican los subtipos del síndrome de intestino irritable (SII). Objetivo: Describir las características y subtipos del SII en niños de Panamá, Ecuador, El Salvador, Nicaragua y México. Material y métodos: Estudio de prevalencia realizado en niños entre los 8 y 18 años de edad con diagnóstico de SII. Los niños respondieron el Cuestionario para Síntomas Gastrointestinales Pediátricos Roma III para Escolares y Adolescentes (QPGS-III) para identificar desordenes gastrointestinales funcionales (DGFs). Se tuvieron en cuenta variables como edad y sexo. Los subtipos de SII se clasificaron en SII con estreñimiento (SII-e), con diarrea (SII-d), mixto (SII-m) y sin subtipo (SII-ss). El análisis estadístico incluyó medidas de tendencia central, t-student a dos colas, chi cuadrado, y prueba exacta de Fisher, siendo una p<0,05 significativa. Resultados: Fueron incluidos 79 niños (54,4% femeninos; 12,1±2,1 años) presentándose SII-ss en 55,7%, SII-e en 15,2%, SII-m en 15,2% y SII-d en13,9%. Predominó el dolor severo la mayor parte del día y con heces mucosas; siendo posibles asociaciones para SII-d el colegio y el sexo. Conclusión: Luego del SII-ss, los SII-e, SII-d y SII-m son similares, siendo los posibles factores de riesgo para SII-d, el colegio público y el género femenino

Introduction: Few pediatric studies classify the irritable bowel syndrome (IBS) subtypes. Objective: To describe the characteristics and subtypes of IBS in children from Panama, Ecuador, El Salvador, Nicaragua and Mexico. Material and methods: Prevalence study performed in children between 8 and 18 years of age with a diagnosis of IBS. The children answered the Questionnaire for Pediatric Gastrointestinal Symptoms Roma III for Schoolchildren and Adolescents (QPGS-III) to identify functional gastrointestinal disorders. Variables such as age and sex were taken into account. The subtypes of IBS were classified in IBS with constipation (IBS-c), with diarrhea (IBS-d), mixed (IBS-m) and without subtype (IBS-ss). Statistical analysis included measures of central tendency, two-tailed student t-test, chi-square test, and Fisher's exact test, with a significant p<0.05. Results: We included 79 children (54.4% female, 12.1±2.1 years) presenting IBS-ss in 55.7%, IBS-c in 15.2%, IBS-m in 15.2% and SII-d in 13.9%. Severe pain predominated most of the day and with mucous stools; possible associations for IBS-d school and sex. Conclusion: After IBS-ss, the IBS-e, IBS-d and IBS-m are similar, being the possible risk factors for IBS-d, the public school and the female gender

Prevalence of irritable bowel syndrome among medical students in hail university, Saudi Arabia

Background: despite the modern society and medical knowledge, irritable bowel syndrome has been common these days in medical students in Hail city

Objectives: irritable bowel syndrome [IBS] is a common gastrointestinal disease presenting with abdominal pain, bloating and change in bowel habit. This study aims to assess the prevalence of irritable bowel syndrome in medical students in Hail's university, Saudi Arabia

Methods: a cross-sectional study on the prevalence of irritable bowel syndrome was randomly distributed among men and women in Hail University in Hail city, of Saudi Arabia from January to February 2018 involving 133 medical student participants

Results: in 18% of the participants have been diagnosed with IBS and 28.5% fit Rome IV criteria for the diagnosis of IBS. Stress with a percentage of 69.2% and lack of exercise 75.9% being the highest risk factors of IBS

Conclusion: our result showed that huge number of medical students are suffering from inflammatory bowel syndrome

Calprotectina fecal: utilidad en el diagnóstico diferencial de enfermedad inflamatoria intestinal y síndrome intestino irritable en adultos / Fecal Calprotectin: utility in the differential diagnosis of inflammatory bowel disease and irritable bowel syndrome in adults

Differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be complex as their symptoms are often similar and unspecific. Fecal biomarkers could be useful to select patients with suspected organic diseases for colonoscopy, with the aim to improve early diagnosis and to avoid unnecessary invasive studies. Fecal calprotectin (FC) is a protein found mainly in neutrophils that is released into the feces as a result of cell disruption and apoptosis. Currently, FC is a simple and non-invasive biomarker of intestinal inflammation. Inflammatory gastrointestinal disorders are associated with high levels of FC, as occurs in IBD. This review focuses on FC as a useful tool for differential diagnosis between IBS and IBD in adults. (AU)

Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome

PURPOSE: Recent studies have revealed close relationships between hepatic injury, metabolic pathways, and gut microbiota. The microorganisms in the intestine also cause irritable bowel syndrome (IBS). The aim of this study was to examine whether IBS was associated with elevated hepatic enzyme [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)], gamma-glutamyl transferase (gamma-GT) levels, and metabolic syndrome (MS). MATERIALS AND METHODS: This was a retrospective, cross-sectional, case-control study. The case and control groups comprised subjects who visited our health promotion center for general check-ups from June 2010 to December 2010. Of the 1127 initially screened subjects, 83 had IBS according to the Rome III criteria. The control group consisted of 260 age- and sex-matched subjects without IBS who visited our health promotion center during the same period. RESULTS: Compared to control subjects, patients with IBS showed significantly higher values of anthropometric parameters (body mass index, waist circumference), liver enzymes, gamma-GT, and lipid levels. The prevalences of elevated ALT (16.9% vs. 7.7%; p=0.015) and gamma-GT (24.1% vs. 11.5%; p=0.037) levels were significantly higher in patients with IBS than in control subjects. A statistically significant difference was observed in the prevalence of MS between controls and IBS patients (12.7% vs. 32.5%; p<0.001). The relationships between elevated ALT levels, MS, and IBS remained statistically significant after controlling for potential confounding factors. CONCLUSION: On the basis of our study results, IBS may be an important condition in certain patients with elevated ALT levels and MS.

Guía de práctica clínica para el diagnóstico y tratamiento del síndrome de intestino irritable en población adulta / Clinical Practice Guideline for the Diagnosis and Management of Adult Patients with Irritable Bowel Syndrome

Objetivo: diseñar una guía de práctica clínica para disminuir la variabilidad injustificada en el diagnóstico y tratamiento de los pacientes mayores de 18 años con síndrome de intestino irritable en Colombia mediante un diagnóstico orientado y unas pautas terapéuticas establecidas. Materiales y métodos: el equipo multidisciplinario que conformó el presente Grupo Desarrollador contó con apoyo de la Asociación Colombiana de Gastroenterología, el Grupo Cochrane ITS y el Instituto de Investigaciones Clínicas de la Universidad Nacional de Colombia. Se desarrollaron preguntas clínicas relevantes y se realizó la búsqueda de guías nacionales e internacionales en bases de datos especializadas. Las guías existentes fueron evaluadas en términos de calidad y aplicabilidad; ninguna de ellas cumplió el criterio de adaptación, por lo que se decidió desarrollar una guía de novo. El Grupo Cochrane realizó la búsqueda sistemática de la literatura. Las tablas de evidencia y recomendaciones fueron realizadas usando la metodología GRADE. Resultados: se desarrolló una guía de práctica clínica basada en la evidencia para el diagnóstico y tratamiento farmacológico de los pacientes mayores de 18 años con síndrome de intestino irritable en Colombia. Conclusiones: se establecieron los criterios clínicos y signos de alarma, las pruebas diagnósticas y las aproximaciones terapéuticas de acuerdo con el síntoma predominante en los pacientes con síndrome de intestino irritable en Colombia.

Objective: To design a clinical practice guideline to reduce unwarranted variation in the diagnosis and treatment of patients over 18 years old with irritable bowel syndrome in Colombia through targeted diagnosis and a treatment guidelines established. Materials and Methods: This guide was developed by a multidisciplinary team with the support of the Colombian Association of Gastroenterology, Cochrane STI Group and Clinical Research Institute of the Universidad Nacional de Colombia. Relevant clinical questions were developed and the search for national and international guidelines in databases was performed. Existing guidelines were evaluated quality and applicability. No guideline met the criteria for adaptation, so the group decided to develop the guideline de novo. Systematic literature searches were conducted by the Cochrane Group. The tables of evidence and recommendations were made based on the GRADE methodology. Results: An evidence-based Clinical Practice Guidelines for the diagnosis and treatment of irritable bowel syndrome in patients over 18 years old was developed for the Colombian context. Conclusions: the clinical criteria and warning signs, diagnostic tests and therapeutic approaches were established in accordance with the predominant symptom in patients with irritable bowel syndrome in Colombia.

Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study / Teste calprotectina fecal semiquantitativa na síndrome do intestino irritável pós-infecciosa e não pós-infecciosa: estudo transversal

CONTEXT AND OBJECTIVE:The presence of a certain degree of inflammation in the gut wall is now accepted in irritable bowel syndrome (IBS). Fecal calprotectin is considered to be a reliable test for detecting intestinal inflammation. Our aim was to assess the presence of inflammation in postinfectious IBS (PI-IBS), compared with non-postinfectious IBS (NPI-IBS). A secondary objective was to determine the usefulness of a rapid fecal calprotectin test in inflammatory bowel diseases (IBD).DESIGN AND SETTING:This was a cross-sectional study. Patients with IBS and IBD at a single tertiary gastroenterology center were prospectively included in this study.METHODS:116 patients with Rome III IBS score (76 females; 48 ± 12 years) were investigated; 24 patients (15 females) had PI-IBS. Intestinal inflammation was assessed using the semiquantitative fecal calprotectin test. The results were expressed as T1, T2 or T3 according to the severity of inflammation (< 15 μg/g; 15-60 μg/g; > 60 μg/g). Using the same test, we evaluated 20 patients with IBD (12 males; 47 ± 13 years).RESULTS:None of the patients with IBS had a T2 or T3 positive test. Among PI-IBS patients, 33% had a T1 positive test. Among NPI-IBS patients, 9.8% had a T1 positive test, which was significantly different to PI-IBS. The calprotectin test was positive in all IBD patients: 80% with T3, 10% with T2 and 10% with T1.CONCLUSIONS:Using a semiquantitative test for fecal calprotectin, positive tests were more frequent in PI-IBS patients than in NPI-IBS patients.

CONTEXTO E OBJETIVO:A presença de certo grau de inflamação na parede do intestino é agora aceita na síndrome do intestino irritável (SII). A calprotectina fecal é considerada teste confiável para detectar inflamação intestinal. Nosso objetivo foi avaliar a presença de inflamação na SII pós-infecciosa (SII-PI), em comparação com a SII não pós-infecciosa (SII-NPI). Um objetivo secundário foi determinar a utilidade de um teste rápido fecal da calprotectina em doenças inflamatórias intestinais (DII).TIPO DE ESTUDO E LOCAL:Este foi um estudo transversal. Pacientes com SII e DII em um único centro terciário de gastroenterologia foram prospectivamente incluídos neste estudo.MÉTODOS:116 pacientes com escore Roma III de SII (76 mulheres, 48 ± 12 anos) foram investigados; 24 pacientes (15 mulheres) tinham SII-PI. Inflamação intestinal foi avaliada pelo teste semi-quantitativo de calprotectina fecal. Os resultados foram expressos como T1, T2 ou T3 de acordo com a gravidade da inflamação (< 15 μg/g; 15-60 mg/g; > 60 mg/g). Usando o mesmo teste, foram avaliados 20 pacientes com DII (12 homens, 47 ± 13 anos).RESULTADOS:Nenhum dos pacientes com SII teve um teste positivo T2 ou T3. Na PI-IBS, 33% tiveram um teste positivo T1. Entre os pacientes SII-NPI, teste T1 positivo estava presente em 9,8%, taxa significativamente diferente quando comparada com SII-PI. O teste de calprotectina foi positivo em todos os pacientes com DII: 80% com T3, 10% com T2 e 10% com T1.CONCLUSÕES:Usando teste semi-quantitativo para calprotectina fecal, relatamos positividade em pacientes SII-PI com mais frequência que em pacientes SII-NPI.

Sensibilidad no celíaca al gluten: Una patología más que responde al gluten / Non-celiac gluten sensitivity: Another condition that responds to gluten

Remission of gastrointestinal and general symptoms after gluten withdrawal has been described in some non-celiac individuals for nearly 30 years. Only recently, efforts have been made to define this entity, now referred to as "non- celiac gluten sensitivity". It includes patients that clinically respond to gluten free diet without exhibiting allergic or autoimmune features to explain such response. Wheat allergy, celiac disease, irritable bowel syndrome and symptoms induced by high FODMAPs (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) consumption are the main differential diagnoses. The relationship with neuropsychiatric disorders such as schizophrenia and autism has not been demonstrated, but currently it gives ground to great hope in families with affected children. Epidemiology of non-celiac gluten sensitivity is not clear. It is described as more common among women and less common in children. Genetic and immune factors, changes in intestinal microbiota and non-gluten components present in wheat grains are main factors postulated in the pathogenesis of this condition. To date, there are no specific biomarkers for non-celiac gluten sensitivity and diagnosis is reached by excluding other causes of disease. A trial with gluten-free diet and subsequent gluten challenge is the methodology most frequently used to confirm diagnosis.

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms / Calprotectina fecal: níveis para o diagnóstico etiológico em pacientes brasileiros com sintomas gastrointestinais

Background Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit Results A total of 279 patients were included in the study, with median age of 39 years (range, 18 to 78 years). After clinical and laboratorial evaluation and considering the final diagnosis, patients were allocated into the following groups: a) Irritable Bowel Syndrome: 154 patients (102 female and 52 male subjects). b) Inflammatory Bowel Diseases group: 112 patients; 73 with Crohn’s disease; 38 female and 35 male patients; 52.1% (38/73) presented active disease, and 47.9% (35/73) had disease in remission and 39 patients with ulcerative colitis;19 female and 20 male patients; 48.7% (19/39) classified with active disease and 49.3% (20/39) with disease in remission. A significant difference (P<0.001) was observed between the median value of fecal calprotectin in Irritable Bowel Syndrome group that was 50.5 µg/g (IQR=16 - 294 µg/g); 405 µg/g (IQR=29 - 1980 µg/g) in Crohn’s disease patients and 457 µg/g (IQR=25 - 1430 µg/g) in ulcerative colitis patients. No difference was observed between the values found in the patients with Crohn’s disease and ulcerative colitis. Levels of fecal calprotectin were significantly ...

Contexto A calprotectina fecal é um biomarcador que pode fornecer informações importantes para o médico, inclusive no atendimento primário, no diagnóstico diferencial de distúrbios gastrointestinais, principalmente as doenças inflamatórias intestinais e a síndrome do intestino irritável. Objetivos Investigar prospectivamente, em adultos brasileiros com queixas gastrointestinais, o valor da calprotectina fecal como biomarcador para o diagnóstico diferencial de distúrbios funcionais e orgânicos e correlacionar as concentrações com a atividade de doenças inflamatórias intestinais. Método O estudo incluiu pacientes consecutivos que apresentavam queixas gastrointestinais e que a dosagem da calprotectina fecal foi recomendada. A dosagem da calprotectina fecal foi obtida utilizando-se o kit ELISA Buhlmann, (Basel, Suiça). Resultados Um total de 279 foram incluídos no estudo, com idade média de 39 anos (variando entre 18 a 78 anos). Após avaliação clínica e laboratorial, e considerando o diagnóstico final, os pacientes foram alocados nos seguintes grupos: a) Grupo Síndrome do Intestino Irritável: 154 pacientes (102 do sexo feminino e 52 indivíduos do sexo masculino). b) grupo Doenças Inflamatórias Intestinais: 112 pacientes; 73 com doença de Crohn; 38 do sexo feminino e 35 pacientes do sexo masculino; 52,1% (38/73) apresentavam doença ativa, e 47,9% (35/73) tiveram a doença em remissão e 39 pacientes com retocolite ulcerativa; 19 do sexo feminino e 20 pacientes do sexo masculino; 48,7% (19/39) classificadas com a doença ativa e 49,3% (20/39) com a doença em remissão. Foi observada uma diferença significativa (P<0,001) entre o valor médio de calprotectina fecal no grupo Síndrome do Intestino Irritável que foi de 50,5 µg/g (16 a 294 µg/g); 405 µg/g (29 a 1980 µg/g), em pacientes com doença de Crohn e 457 µg/g (25 a1430 µg/g), em pacientes com retocolite ulcerativa. Não foram observadas diferenças entre os valores encontrados nos pacientes com ...

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects

Small intestinal bacterial overgrowth (SIBO) can partly explain irritable bowel syndrome (IBS), and rifaximin has been observed to improve abdominal symptoms in nonconstipated IBS patients. However, there are few reports on the association of the rifaximin treatment periods with the results of a lactulose breath test (LBT). Therefore, we performed a retrospective review of patient charts to investigate the relation between the rifaximin treatment periods with LBT results in nonconstipated IBS patients. We also evaluated the time to achieve a symptomatic improvement in the IBS patients as compared to the changes in the LBT. We reviewed the charts for patients who showed IBS symptoms with documented positive results for LBT during their initial visit and who had a follow-up LBT after treatment with rifaximin. The LBT values were compared to the subjects' symptom scores. A total of 102 subjects had a follow-up LBT to assess LBT normalization. The subjects were divided into groups according to treatment periods of 4 weeks (n = 36), 8 weeks (n = 43), and 12 weeks (n = 23). The groups with a longer treatment exhibited an increase in the hydrogen gas value at 90 min and its sum during 90 min at the initial LBT. There were significant differences in hydrogen gas value at 90 min and in its sum during 90 min at the initial LBT between the groups treated for 4 and 12 weeks. The most significant treatment response was observed during the first 4 weeks for all treatment groups. Symptomatic improvement occurred earlier than LBT normalization in the treatment period over 4 weeks. The results indicate that different rifaximin treatment periods are needed in accordance with LBT levels to effectively eradicate SIBO.

Prevalencia del síndrome intestino irritable en la población adulta venezolana / Prevalence of irritable bowel syndrome in venezuelan adults

El síndrome del intestino irritable (SII) es un trastorno digestivo funcional que afecta del 10 al 20% de la población general. Existen pocos estudios en Latinoamérica que muestren su prevalencia nacional, y en Venezuela no disponemos de investigación que reporte tan importante cifra. Estudio multicéntrico, descriptivo, transversal, durante los meses abril y mayo del 2011. Se utilizó el cuestionario validado de la Fundación Roma, con quienes firmamos convenio como Servicio de Gastroenterología del Hospital Vargas de Caracas. Se seleccionaron al azar 15 estados, en cada uno un municipio, y de estos lugares como iglesias, centros comerciales, reuniones de Consejos Comunales, paradas de autobuses, etc. Los valores obtenidos fueron transcritos en una base de datos en Excel y procesados con EPIDAT 3.1. De 1781 personas encuestadas, 299 presentaron criterios clínicos diagnósticos para SII de acuerdo a Roma III. La prevalencia nacional del SII fue de 16,80%, correspondiendo 81,6% a mujeres (244) y 18,4% a hombres (55). El grupo etario entre 38 y 47 años fue el más afectado (26,43%) y el subtipo mixto el más predominante. La prevalencia del SII en la población adulta venezolana según los criterios de Roma III es de 16,80%

Irritable bowel syndrome (IBS) is a functional digestive disorder that affects 10 to 20% of the general population. Few studies exist in Latin America that shows the national prevalence, and in Venezuela we don´t have investigation resources that support those numbers. Multicenter study, descriptive, transversal, during the months April and May 2011. The validated Roma Foundation questionnaire was used. This Foundation authorized its use by the Service of Gastroenterology Hospital Vargas de Caracas. 15 states were randomly selected, in each state one municipality, and in those places as churches, shopping centers, comunity meeting, bus stops, etc. The values obtained were transcribed into a database in Excel and processed EPIDAT 3.1. Of 1781 people encuested, 299 met the criteria for IBS according to Rome III. The national prevalence of IBS was 16.80%, with 81.6% women (244) and 18.4% men (55). The age group between 38 and 47 years was the most affected (26.43%) and the mix was the most predominant subtype. The prevalence of IBS in the Venezuelan adult population according to Rome III criteria is 16.80%

Utilidad de la calprotectina fecal en la patología intestinal: experiencia inicial / Fecal calprotectin and the utility in intestinal pathology: initial experience

Background: Intestinal pathology has a wide spectrum of symptoms, when these are unspecific endoscopic study is generally required in order to differentiate organic and functional disease. Fecal calprotectin (FC) is a reliable and non-invasive tool that can be used to infer damage in the intestinal mucosa, especially in Inflammatory Bowel Disease (IBD). Objective: To evaluate our initial experience measuring FC and its usefulness in medical practice. Materials and Methods: Using information of patients with FC indicated for unspecific gastrointestinal (GI) symptoms between January 2011 and March 2012. Patients were classified in: group 1 (G1 with IBD) and group 2 (without organic GI disease). Three groups were established according to FC results: negative (< 15 ug/g), intermediate (15-60 ug/g) and positive (> 60 ug/g). Concordance between results and physicians’ behavior was established. Results: In the period mentioned above a total of 64 patients (24 G1-40 G2) were selected. In G1, FC levels were negative, intermediate and positive in 8, 3 and 13 patients, respectively, being concordant in a 100, 100 and 84.6 percent, respectively. Only four patients needed a colonoscopy to adjust treatment. Mainly, there was a favorable clinical response. In G2, results on FC were negative in 19, intermediate in 8 and positive in 13 patients, in which concordance was established with the presence of organic intestinal pathology with a 94.7 percent, 87.5 percent and 92.3 percent, respectively. Conclusions: This study confirms that in our population, there is a good correlation between FC results and physicians behavior, especially in patients with IBD.

Introducción: En pacientes con síntomas gastrointestinales (GI) inespecíficos, es difícil diferenciar entre patología orgánica y funcional, requiriendo muchas veces de estudios endoscópicos asociados. La calprotectina fecal (CF) ha demostrado ser un marcador confiable y menos invasivo en la evaluación de la inflamación de la mucosa intestinal, especialmente en enfermedad inflamatoria intestinal (EII). Objetivo: Evaluar la experiencia inicial en la medición de CF y su utilidad en la práctica clínica. Material y Métodos: Utilizando datos de pacientes sometidos a medición de CF secundario a síntomas GI inespecíficos, entre enero de 2011 y marzo de 2012. Se clasificó en: grupo 1 (G1 pacientes con diagnóstico de EII) y grupo 2 (G2 sin morbilidad GI). Se midió CF y según el resultado se establecieron tres grupos: negativo (< 15 ug/g), intermedio (15-60 ug/g), y positivo (> 60 ug/g). Se buscó concordancia entre CF y conducta médica. Resultados: Se seleccionaron 64 pacientes (24 G1 y 40 G2). En G1, los niveles de CF negativa, intermedia y positiva, fueron 8, 3 y 13 respectivamente. La conducta médica fue concordante en 100, 100 y 84,6 por ciento. Sólo 4 pacientes requirieron de colonoscopia para modificar tratamiento. La mayoría tuvo respuesta clínica favorable. En G2, los resultados fueron 19 negativos, 8 intermedios y 13 positivos, donde según hallazgo de patología orgánica hubo 94,7 por ciento, 87,5 por ciento y 92,3 por ciento, de concordancia con el resultado de CF respectivamente. Conclusión: Este estudio confirma que en nuestra población existe buena correlación entre el resultado de CF y la conducta médica, sobre todo en pacientes con EII.

Association between Symptoms of Irritable Bowel Syndrome and Methane and Hydrogen on Lactulose Breath Test

Whether hydrogen and methane gas produced during lactulose breath test (LBT) are associated with symptoms of irritable bowel syndrome (IBS) is not determined. We aimed to investigate whether hydrogen and methane on LBT are associated with IBS symptoms. Sixty-eight IBS patients meeting the Rome III criteria for IBS, and 55 healthy controls, underwent LBT. The IBS subjects recorded their customary gastrointestinal symptoms on a questionnaire using visual analogue scales. LBT positivity was defined to be above 20 ppm rise of hydrogen or 10 ppm rise of methane within 90 min. Gas amounts produced during LBT were determined by calculating area under the curve of hydrogen and methane excretion. Symptom severity scores were not different between the LBT (+) IBS and LBT (-) IBS subjects and also between methane producers and non-methane producers. Gas amounts produced during LBT were not associated with IBS symptoms, except a weak correlation between total gas amounts and a few IBS symptoms such as bloating (r = 0.324, P = 0.039), flatulence (r = 0.314, P = 0.046) and abdominal pain (r = 0.364, P = 0.018) only in LBT (+) IBS. In conclusion, hydrogen and methane gas on LBT are not useful for predicting the customary symptoms and subtypes of IBS.